Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dow Pharmaceutical Sciences Inc.

http://www.dowpharm.com

Latest From Dow Pharmaceutical Sciences Inc.

FDA Looks Ahead To Complex Product-Specific Guidances

The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

Guidance Documents Generic Drugs

Exploring the US FDA's Upcoming Complex Generic Product-Specific Guidance Lists

The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

Guidance Documents Generic Drugs

Valeant Backs Strategy With Solid Deal Record

Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.

BioPharmaceutical North America

US Capitol Capsule: Drug price 'yellow' signs: market canaries or lemons?

The "troubling" trends in the rising costs to US consumers of prescription drugs, including generics, is a big yellow warning sign the biopharmaceutical market is out of balance, largely due to a lack of transparency in how medicines are priced, insisted Dr Stephen Schondelmeyer, a professor of pharmaceutical management and economics and director of the PRIME Institute at the University of Minnesota.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register